91st General Assembly
Summary of HB2256
   [ Home ]   [ Back ]   [ Legislation ]
Legislation:  
Please enter a bill number.



 Full Text  Bill Status
House Sponsors:
O'BRIEN-HASSERT-BURKE-LOPEZ-HAMOS, LYONS,JOSEPH, 
   CURRY,JULIE, CROTTY, FOWLER, PERSICO, HOFFMAN, WAIT, 
   BRADLEY, DAVIS,MONIQUE, HARRIS AND MCGUIRE.

Senate Sponsors:
SYVERSON-MAHAR-FAWELL-SHADID-MUNOZ

Short description: 
DISPENSING GENERIC DRUGS                                                   

Synopsis of Bill as introduced:
        Amends the Pharmacy Practice Act and the Illinois Food, Drug  and      
   Cosmetic  Act.  Provides that pharmacists may substitute generic brand      
   drugs, provided that the selected drug has been rated  therapeutically      
   equivalent  to  the  prescribed drug in the Orange book or meets other      
   criteria. Effective immediately.                                            
        HOUSE AMENDMENT NO. 1.                                                 
        Deletes a provision in the Illinois Food, Drug and  Cosmetic  Act      
   that  provides  that  the determination of drug products that have not      
   been rated therapeutically equivalent in the Orange book, but that may      
   be selected shall be recommended by a Technical  Advisory  Council  of      
   the Department.                                                             
          BALANCED BUDGET NOTE, H-AM 1 (Bureau of the Budget)                  
          Since this bill is not a supplemental appropriation bill,            
          the Balanced Budget Note Act is inapplicable.                        
          JUDICIAL NOTE, H-AM 1 (Administrative Office of Ill. Courts)         
          There would be neither a decrease nor an increase in the number      
          of judges needed.                                                    
        GOVERNOR'S AMENDATORY VETO MESSAGE                                     
        Recommends changing the bill to provide that the therapeutically       
   equivalent generic brand that the pharmacist may substitute for name        
   brands may not be a critical dose drug and that the Technical Advisory      
   Council be allowed to consider drugs that require a prescription and        
   are legally marketed in the United States according to FDA regula-          
   tions. Recommends a definition for "critical dose drug".                    
 
Last action on Bill: BILL DEAD-AMENDATORY VETO

   Last action date: 99-11-18

           Location: House

 Amendments to Bill: AMENDMENTS ADOPTED: HOUSE -   1     SENATE -   0


   END OF INQUIRY 



 Full Text  Bill Status